Iterum Therapeutics (ITRM)
NASDAQ: ITRM
· Real-Time Price · USD
0.94
-0.02 (-2.06%)
At close: Jun 05, 2025, 3:59 PM
-2.06% (1D)
| Bid | 0.93 |
| Market Cap | 37.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.56M |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -1 |
| Forward PE | -13.67 |
| Analyst | Buy |
| Ask | 1 |
| Volume | 181,948 |
| Avg. Volume (20D) | 442,849 |
| Open | 0.93 |
| Previous Close | 0.96 |
| Day's Range | 0.93 - 0.97 |
| 52-Week Range | 0.81 - 3.02 |
| Beta | 2.82 |
About ITRM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ITRM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ITRM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-15.87%
Iterum Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
7 months ago
+60.68%
Iterum Therapeutics shares are trading higher after the FDA approved the company's new drug application for ORLYNVAH for the treatment of uncomplicated urinary tract infections.
